Interventional Orthopedic Solutions Rochester Enters Into a Partnership with Regenexx®

Interventional Orthopedic Solutions Rochester is establishing its commitment to excellence in the field of Regenerative Orthopedics by entering into a partnership with Regenexx®, a worldwide network of specially trained physicians providing advanced, research-driven, regenerative orthopedic treatments.

The alliance brings cutting-edge, non-surgical orthopedic treatments to Minnesota residents suffering from sports injuries, spine pain, or degenerative diseases such as osteoarthritis.

“Being selected to represent the Regenexx brand in Minnesota speaks to the quality, skill, and care that we provide our patients,” said Catherine McBride, co-founder of the Rochester-based clinic. “Interventional Orthopedic Solutions is focused on providing the highest level of non-surgical orthopedic care in Minnesota and our partnership with Regenexx helps us achieve that goal.”

Interventional Orthopedic Solutions Rochester was founded by Dr. Russell Bergum, a long-time Minnesotan and a specialist in regenerative medicine and interventional orthopedics, and is focused on the treatment of musculoskeletal injuries and degenerative orthopedic conditions.

“All of our procedures are based on published, peer-reviewed research and incorporate the extensive Regenexx outcomes database tracking patient results from 2005 to the present, to guide treatment plans,” said Dr. Bergum, founder of IOS-Rochester. “Our goal is to get you back into doing the things you love to do. This is now possible through the state-of-the-art non-surgical orthobiologic treatments that we offer.”

Interventional Orthobiologics is a specialty that focuses on using your body’s natural healing agents to treat orthopedic injuries with the goal of reducing pain and improving joint function. The variety of orthobiologics available to Regenexx physicians, such as bone marrow aspirate concentrate (which contains stem cells) and platelet-rich plasma (PRP), allow them to create a treatment plan to best support your recovery. Regenexx procedures can be used in the treatment of conditions such as arthritis, back pain, and injury to ligaments, tendons, cartilage, spinal discs, or bones.

Regenexx physicians are required to have extensive experience and training in performing precise injection-based procedures using image guidance for a range of body parts and injuries. With strict acceptance criteria, Regenexx only chooses the most qualified physicians to join their network. Interventional Orthopedic Solutions Dr. Russell Bergum is ranked among them.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”